Neurocrine Biosciences survey finds one in five adults with tardive dyskinesia quit jobs
Updated
Updated · PR Newswire · May 4
Neurocrine Biosciences survey finds one in five adults with tardive dyskinesia quit jobs
6 articles · Updated · PR Newswire · May 4
The US Ipsos survey of 100 people, released during Tardive Dyskinesia Awareness Week, found 12 of 59 eligible adults left jobs and all missed eight hours weekly before treatment.
Nineteen respondents said they reduced or changed work responsibilities because of symptoms, while surveyed caregivers also reported missed work and disruptions before their loved ones began treatment.
Neurocrine said TD affects at least 800,000 US adults, about 60% remain undiagnosed, and only around one in 10 receive a VMAT2 inhibitor despite guideline-backed treatment recommendations.
With 60% of cases undiagnosed, what is the true economic toll of Tardive Dyskinesia on the U.S. workforce?
Why do 90% of TD patients miss out on recommended treatments that could potentially save their careers?
Is Neurocrine's survey a public service or a marketing tactic for its $2.5 billion drug, INGREZZA®?